LOX and neoplasm: Notably, when a COX-2 inhibitor (NS-398) or LOX inhibitor (MK-886) was added to the neutrophil–lipid treatment system, the reactivation capacity of dormant tumor cells was significantly attenuated (Fig. S11I).